← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Okava Pharmaceuticals, Inc.
San Francisco, CA
$499,280
Total funding
1
Grants
Funding over time
peak $249.7K · FY2020–21$250K$187.5K$125K$62.5K$0
'20
'21
Funding mix
By agency
FDA$499,280 · 1
By mechanism
R01$499,280 · 1
Investigators at Okava Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Reasonable Expectation of Effectiveness Clinical Trial of OKV-1001 for the Treatment of Primary (Non-Associative) Immune-Mediated Hemolytic Anemia in Dogs$249,657
R01 · FY2020 · FD
A Reasonable Expectation of Effectiveness Clinical Trial of OKV-1001 for the Treatment of Primary (Non-Associative) Immune-Mediated Hemolytic Anemia in Dogs$249,623
R01 · FY2021 · FD